LCAR-HL30 cells
Phase 1Biologic
LCAR-HL30 cells is one of 20 biologic programs targeting Anaplastic Large Cell Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Anaplastic Large Cell Lymphoma
#DrugCompanyPhaseTrials
1Lorbrena
PfizerApproved
Xalkori
PPrism Pharmaceuticals
Approved
Gleevec
NovartisApproved
Ixempra
RR-Pharm
Approved
Navelbine
PPierre Fabre Medicament
Approved
Alecensa
RochePhase 1
Copiktra
SSecuraBio
Phase 1
Atgam
NovartisPreclinical
Idamycin
PfizerPreclinical
Neoral
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LCAR-HL30 cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- RRuijin Hospital